Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN-Reference-Cited by-同舟云学术

Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN

Published:2022-01 Issue: Volume:57 Page:103367
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Newsome Scott D.,Scott Thomas F.,Arnold Douglas L.,Altincatal Arman,Naylor Maria L.

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference34 articles.

1. Number of MRI T1-hypointensity corrected by T2/FLAIR lesion volume indicates clinical severity in patients with multiple sclerosis;Akaishi;PLoS ONE,2020

2. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial;Arnold;BMC Neurol.,2017

3. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis;Arnold;BMC Neurol.,2014

4. Peginterferon beta-1a reduces the number of black holes evolved from acute MRI lesions in newly diagnosed patients with relapsing-remitting multiple sclerosis: A post hoc analysis of ADVANCE;Arnold,2018

5. Peginterferon beta-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting multiple sclerosis. Ther;Arnold;Adv. Neurol. Disord.,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diffusion basis spectrum imaging and diffusion tensor imaging predict persistent black hole formation in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-04

2. Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies;Therapeutic Advances in Neurological Disorders;2024-01